Glenmark Pharma Latest News

  1. The company has initiated Phase IIb dose range finding study for GRC 27864
    Date:16-01-2018
  2. GRC 27864 is a potent, selective, and orally bioavailable inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), a novel therapeutic target in pain management
    Date:15-01-2018
  3. GRC 27864 is a potent, selective, and orally bioavailable inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), a novel therapeutic target in pain management
    Date:15-01-2018
  4. The biosimilar will be marketed by Glenmark under the brand name ADALY
    Date:05-01-2018
  5. The biosimilar will be marketed by Glenmark under the brand name ADALY
    Date:04-01-2018
  6. According to IQVIA sales data for the 12 month period ending October 2017, the Minastrin 24 Fe Tablets market achieved annual sales of approximately $337.0 million
    Date:27-12-2017
  7. According to IQVIA sales data for the 12 month period ending October 2017, the Minastrin 24 Fe Tablets market achieved annual sales of approximately $337.0 million
    Date:27-12-2017
  8. The company is planning to submit its first NDA to the USFDA for Ryaltris for the treatment of patients with SAR in the first quarter of CY 2018
    Date:14-12-2017
  9. The company is planning to submit its first NDA to the USFDA for Ryaltris for the treatment of patients with SAR in the first quarter of CY 2018
    Date:14-12-2017
  10. GBR 1342 simultaneously targets CD38, as well as the CD3 T cell co-receptor
    Date:08-12-2017
Return to Top
Connect with us Facebook
Connect with us Facebook
Connect with us Linkedin
Connect with us Pintrest
Connect with us Google Plus
Connect with us You Tube
Connect with us Mobile App
 
 
Request a Call Back
Mobile
Invalid Mobile Number
x
Thanks. We will call you shortly.